The burgeoning landscape of therapy for weight management and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant variations in their pharmacological profiles and clinical study results are emerging. Retatrut… Read More

Emerging in the landscape of weight management management, retatrutide presents a distinct strategy. Different from many available medications, retatrutide operates as a twin agonist, concurrently engaging both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) sensors. This simultaneous stimulation fosters various beneficia… Read More